4 research outputs found
Recommended from our members
The rational design of drug crystals to facilitate particle size reduction. Investigation of crystallisation conditions and crystal properties to enable optimised particle processing and comminution.
Micronisation of active pharmaceutical ingredients (APIs) to achieve desirable quality attributes for formulation preparation and drug delivery remains a major challenge in the pharmaceutical sciences. It is therefore important that the relationships between crystal structure, the mechanical properties of powders and their subsequent influence on processing behaviour are well understood. The aim of this project was therefore to determine the relative importance of particle attributes including size, crystal quality and morphology on processing behaviour and the characteristics of micronised materials. It was then subsequently intended to link this behaviour back to crystal structure and the nature of molecular packing and intermolecular interactions within the crystal lattice enabling the identification of some generic rules which govern the quality of size reduced powders. In this regard, different sieve fractions of lactose monohydrate and crystal variants of ibuprofen and salbutamol sulphate (size, morphology and crystal quality) were investigated in order to determine those factors with greatest impact on post-micronisation measures of particle quality including particle size, degree of crystallinity and surface energy.
The results showed that smaller sized feedstock should typically be used to achieve ultrafine powders with high crystallinity. This finding is attributed to the reduced number of fracture events necessary to reduce the size of the particles leading to decreases in milling residence time. However the frequency of crystal cracks is also important, with these imperfections being implicated in crack propagation and brittle fracture. Ibuprofen crystals with a greater number of cracks showed a greater propensity for comminution. Salbutamol sulphate with a high degree of crystal dislocations however gave highly energetic powders, with reduced degree of crystallinity owing to the role dislocations play in facilitating plastic deformation, minimising fragmentation and extending the residence of particles in the microniser. Throughout these studies, morphology was also shown to be critical, with needle like morphology giving increased propensity for size reduction for both ibuprofen and salbutamol sulphate, which is related to the small crack propagation length of these crystals. This behaviour is also attributed to differences in the relative facet areas for the different morphologies of particles, with associated alternative deformation behaviour and slip direction influencing the size reduction process. Molecular modelling demonstrated a general relationship between low energy slip planes, d-spacing and brittleness for a range of materials, with finer particle size distributions achieved for APIs with low value of highest d-spacings for identified slip planes. The highest d-spacing for any material can be readily determined by PXRD (powder x-ray diffraction) which can potentially be used to rank the milling behaviour of pharmaceutical materials and provides a rapid assessment tool to aid process and formulation design.
These studies have shown that a range of crystal properties of feedstock can be controlled in order to provide micronised powders with desirable attributes. These include the size, morphology and the density of defects and dislocations in the crystals of the feedstock. Further studies are however required to identify strategies to ensure inter-batch consistency in these attributes following crystallisation of organic molecules
Influence of solvent on the morphology and subsequent comminution of ibuprofen crystals by air jet milling
Crystal morphology plays an important role in drug processing and delivery, which may be controlled during crystallisation. In this study, ibuprofen particles with different size and morphology were produced by controlled crystallisation in order to evaluate their impact on particle size reduction. Results suggest that the micronisation behaviour of ibuprofen was markedly influenced by the morphology and size of starting materials. It was possible to reduce the size of ibuprofen particles to sizes less than 5 μm during dry milling, which is markedly below the reported brittle-ductile transition size. Results also indicate that the particle size reduction mechanism is influenced by the size and morphology of the starting ibuprofen crystals. Dissolution behaviour of ibuprofen was shown to be influenced by the solid surface chemistry of micronised drug particles. The molecular modelling study provided deeper understanding of the experimental findings observed in this study. © 2011 Wiley Periodicals, Inc
Development and Optimization of Epigallocatechin-3-Gallate (EGCG) Nano Phytosome Using Design of Experiment (DoE) and Their In Vivo Anti-Inflammatory Studies
Inflammation is responsible for the development of many diseases that make up a significant cause of death. The purpose of the study was to develop a novel nanophytosomal preparation of epigallocatechin-3-gallate (EGCG) and egg phospholipid complex that has a lower particle size with higher drug loading capability, physical stability and anti-inflammatory activities. The impact of different factors and material characteristics on the average particle size was studied along with the drug loading of phytosome using design of experiment (DoE). The in vivo anti-inflammatory study was evaluated using a rat model to investigate the performance of EGCG nanophytosome. UHPLC results showed that 500 µg of EGCG were present in 1 mL of green tea extract. SEM data exhibited that phytosome (phospholipid-drug complex) was in the nanosize range, which was further evident from TEM data. Malvern Zetasizer data showed that the average particle size of the EGCG nanophytosome was in the range of 100–250 nm. High drug loading (up to 90%) was achieved with optimum addition rate, stirring temperature and phospholipid concentration. Stability study data suggest that no significant changes were observed in average particle size and drug loading of nanophytome. The in vivo anti-inflammatory study indicated a significant anti-inflammatory activity of green tea extract, pure EGCG and its phytosomal preparations (p ≤ 0.001) against acute paw edema
The impact of formulation attributes and process parameters on black seed oil loaded liposomes and their performance in animal models of analgesia
This study aimed to formulate black seed oil (Nigella sativa) loaded liposomes using the ethanol injection method to enhance oral bioavailability and improve therapeutic activity in small animal studies of analgesia. The impact of formulation attributes and process parameters on the liposomal system was evaluated with key quality attributes being particle size, morphology, and entrapment efficiency. The particle size and entrapment efficiency of the liposome preparation were found to be between the range of 50–900 nm and 34–87% respectively. Particle size distribution data suggested that increasing the percentage of oil, up to a certain concentration, reduced the size of the liposomes significantly from 520 ± 81.2 nm to 51.48 ± 1.31 nm. Stirring and injection rate were shown to have marked impact on the average particle size of liposome. It was observed that entrapment efficiency of liposomes was greatly influenced by the amount of cholesterol and type of cryoprotectant used during formulation. The stability study indicated that the liposomal preparation was stable at ambient conditions for one month. In vivo studies showed that the liposomal preparation demonstrated significant analgesic activity in mice